1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Avon Technologies PLC

Avon Technologies PLC

AVON.L
Avon Technologies PLCGB flagLondon Stock Exchange
1,800.00
GBp
+10.00
- -
534.65MMarket Cap
Avon Technologies PLC
AVON.L
(London Stock Exchange)

Recent

price

1,800.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
6.53
5.94
5.9
6.85
6.78
6.76
6.15
7.01
7.07
5.17
6.99
8.1
8.69
8.06
9.2
10.65
Revenue per Share
0.24
0.39
0.43
0.49
0.59
0.69
0.76
0.95
0.91
0.57
5.61
-0.83
-0.25
-0.48
0.1
0.35
Basic EPS, GAAP
0.07
0.1
0.22
0.06
0.81
0.55
1.01
1.19
0.96
0.49
-0.43
-0.14
0.85
-0.13
1.43
0.65
Free Cash Flow per Basic Share
- -
0.04
0.05
0.06
0.08
0.09
0.1
0.14
0.18
0.22
0.29
0.39
0.44
0.44
0.23
0.24
Dividend per Share
-1.47
-0.79
-0.6
-0.76
-0.5
0.23
-0.08
0.61
1.37
1.73
6.24
5.42
5.61
3.91
4.28
4.33
Book Value per Share
- -
0.59
0.59
0.23
0.42
0.05
-0.23
0.67
1.42
1.61
4.58
0.8
1.3
0.67
1.34
1.74
Tangible Book Value per Share
28
28
29
29
30
30
30
30
31
31
31
31
30
30
30
29
Basic Weighted Avg Shares
186
168
172
202
203
204
186
213
216
158
214
248
264
244
275
314
Sales/Revenue/Turnover
7.6
10.35
10.9
10.41
11.48
14.06
12.11
14.26
14.32
7.71
4.17
-11.68
4.17
-5.17
3.89
6.12
Operating Margin (%)
7
7
8
10
10
12
16
17
14
8
19
29
22
21
20
21
Depreciation Expense
7
11
13
14
18
21
23
29
28
17
171
-26
-8
-14
3
10
Net Income, GAAP
39.36
30.3
28.86
28.75
22.02
14.98
- -
- -
8.33
- -
- -
- -
5
- -
- -
21.37
Effective Tax Rate (%)
3.68
6.62
7.34
7.08
8.66
10.17
12.32
13.51
12.93
10.98
80.24
-10.31
-2.88
-5.91
1.09
3.28
Profit Margin (%)
14
18
14
18
14
11
11
45
69
84
168
81
63
86
59
70
Working Capital
21
19
14
18
- -
17
- -
- -
14
14
26
66
73
94
76
79
LT Debt
14
33
39
33
41
64
55
74
97
93
230
205
210
159
166
167
Total Equity
26.64
26.47
22.92
24.51
31.95
33.08
- -
- -
27.34
- -
- -
- -
3.7
- -
- -
6.1
Return on Invested Capital (%)
-35.43
-219.59
-939.13
-395.78
-185.05
356.59
- -
- -
74.63
- -
- -
- -
-1.38
- -
- -
7.29
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
92.26
36.59
140.66
-14.35
-4.52
-9.99
2.44
8.06
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.76%
-5.55%
0.12%
Free Cash Flow
-228.67%
-426.45%
-54.8%
Net Income, GAAP
91.1%
5.34%
243.33%
Sales/Revenue/Turnover
5.75%
8.37%
14.15%
Total Cash Common Dividend
- -
- -
5.88%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
275
2025
- -
- -
- -
- -
314
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.1
2025
- -
- -
- -
- -
0.35
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.23
2025
- -
- -
- -
- -
0.24
2026
- -
- -
- -
- -
- -
Similar Companies
DuoGenic StemCells corporation (7607.TWO)
Metir plc (MET.L)
Embla Medical hf. (EMBLA.CO)
United American Healthcare Corporation (UAHC)
Axogen, Inc. (0HKD.L)
Carl Zeiss Meditec AG (CZMWF)
Business
Avon Technologies PLC Avon Technologies plc (AVON.L) designs, manufactures and supplies mission-critical respiratory and head protection systems for military, law enforcement and first responder customers worldwide; its core offerings encompass respirators and accessories, powered and supplied air systems, rebreathers, chemical biological radiological nuclear (CBRN) protective wear, ballistic helmets, bump helmets, and helmet liner and retention systems under the Avon Protection and Team Wendy brands. Founded in 1890 and headquartered in Melksham, Wiltshire, United Kingdom, the company operates manufacturing facilities in the UK and North America, serving primary markets including the US Department of Defense, UK Ministry of Defence, NATO allies and commercial end-users with a focus on user-centric design, advanced materials and vertically integrated production. Recent developments include a record $225 million closing order book as of September 2024 reflecting strong demand, with key wins such as up to £38 million UK Ministry of Defence General Service Respirator and filter contracts, a new respirator award for the Australian Defence Force, $34 million US Department of Defense delivery orders for Advanced Combat Helmet Generation II, a $42 million Next Generation Integrated Head Protection System order from the US Army, rebreather contracts from New Zealand and German Navies, and three new US Department of Defense Programs of Record for Hood Mask Interface development; the company continues execution of its STAR strategy emphasizing continuous improvement initiatives that delivered 21% productivity gains and 54% scrap reduction versus fiscal 2023, alongside helmet manufacturing site consolidation targeted for completion mid-2025 to enhance margins and efficiency.

Company News

APIChatGPT